


What is important about the COVID-19 variants?

- Pandemic trajectory
- Double masks
- Monoclonal antibodies
- Vaccinations
- Mandates/restrictions/link to healthcare system impact and activity

Variant of coronavirus from UK detected at UW, university says

The Seattle Times, 2/9/21

Feb. 9, 2021 at 7:31 pm



CDC: <https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html>

MMWR:
<https://www.cdc.gov/mmwr/volumes/70/wr/mm7003e2.htm>

Medrxiv:
<https://www.medrxiv.org/content/10.1101/2021.02.06.21251159v1>

<https://www.medrxiv.org/content/10.1101/2021.02.02.21250985v1>

Emerging SARS-CoV-2 Variants

- [CDC site](#)
- Variants of concern:
 - UK- VOC 202012/01, lineage B.1.1.7, 20I/501Y.V1
 - SA- lineage B.1.351, 20H/501Y.V2, **E484K**
 - Brazil- lineage P.1, 20J/501Y.V3, **E484K**

VOC 202012/01, lineage B1.1.7, 20I/501Y.V1


- “Spike gene target failure” due to 6nt deletion
- First detected 10/12/20, represented 3% of sequences
- By 11/30/20, represented >90% of sequences and is now fixed
- Growth rate 40% to 70% higher, possibly due to better ACE2 binding
- Arrived in U.S. in November 2020, as of January in 30 states
- No evidence that variant impacts vaccine efficacy

Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Nicole L. Washington^{1,*}@, Karthik Gangavarapu^{2,*}@, Mark Zeller², Alexandre Bolze¹, Elizabeth T. Cirulli¹, Kelly M. Schiabor Barrett¹, Brendan B. Larsen³, Catelyn Anderson², Simon White¹, Tyler Cassens¹, Sharoni Jacobs¹, Geraint Levan¹, Jason Nguyen¹, Jimmy M. Ramirez III¹, Charlotte Rivera-Garcia¹, Efren Sandoval¹, Xueqing Wang¹, David Wong¹, Emily Spencer², Refugio Robles-Sikisaka², Ezra Kurzban², Laura D. Hughes¹², Xianding Deng⁴, Candace Wang⁴, Venice Servellita⁴, Holly Valentine⁵, Peter De Hoff⁶, Phoebe Seaver⁵, Shashank Sathe⁵, Kimberly Gietzen⁶, Brad Sickler⁶, Jay Antico⁶, Kelly Hoon⁶, Jingtao Liu⁶, Aaron Harding⁷, Omid Bakhtar⁷, Tracy Basler⁸, Brett Austin⁸, Magnus Isaksson¹, Phillip G. Febbo⁶, David Becker¹, Marc Laurent¹, Eric McDonald⁸, Gene W. Yeo⁵, Rob Knight⁵, Louise C. Laurent⁵, Eileen de Feo⁶, Michael Worobey³, Charles Chiu^{4,9}, Marc A. Suchard¹⁰, James T. Lu¹, William Lee^{1,#}, Kristian G. Andersen^{2,11,#}@

LINK:

<https://www.medrxiv.org/content/10.1101/2021.02.06.21251159v1>




Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Nicole L. Washington^{1,*}@, Karthik Gangavarapu^{2,*}@, Mark Zeller², Alexandre Bolze¹, Elizabeth T. Cirulli¹, Kelly M. Schiabor Barrett¹, Brendan B. Larsen³, Catelyn Anderson², Simon White¹, Tyler Cassens¹, Sharoni Jacobs¹, Geraint Levan¹, Jason Nguyen¹, Jimmy M. Ramirez III¹, Charlotte Rivera-Garcia¹, Efren Sandoval¹, Xueqing Wang¹, David Wong¹, Emily Spencer², Refugio Robles-Sikisaka², Ezra Kurzban², Laura D. Hughes¹², Xianding Deng⁴, Candace Wang⁴, Venice Servellita⁴, Holly Valentine⁵, Peter De Hoff⁶, Phoebe Seaver⁵, Shashank Sathe⁵, Kimberly Gietzen⁶, Brad Sickler⁶, Jay Antico⁶, Kelly Hoon⁶, Jingtao Liu⁶, Aaron Harding⁷, Omid Bakhtar⁷, Tracy Basler⁸, Brett Austin⁸, Magnus Isaksson¹, Phillip G. Febbo⁶, David Becker¹, Marc Laurent¹, Eric McDonald⁸, Gene W. Yeo⁵, Rob Knight⁵, Louise C. Laurent⁵, Eileen de Feo⁶, Michael Worobey³, Charles Chiu^{4,9}, Marc A. Suchard¹⁰, James T. Lu^{1,#}, William Lee^{1,#}, Kristian G. Andersen^{2,11,#}@

LINK:

<https://www.medrxiv.org/content/10.1101/2021.02.06.21251159v1>




Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Nicole L. Washington^{1,*}@, Karthik Gangavarapu^{2,*}@, Mark Zeller², Alexandre Bolze¹, Elizabeth T. Cirulli¹, Kelly M. Schiabor Barrett¹, Brendan B. Larsen³, Catelyn Anderson², Simon White¹, Tyler Cassens¹, Sharoni Jacobs¹, Geraint Levan¹, Jason Nguyen¹, Jimmy M. Ramirez III¹, Charlotte Rivera-Garcia¹, Efren Sandoval¹, Xueqing Wang¹, David Wong¹, Emily Spencer², Refugio Robles-Sikisaka², Ezra Kurzban², Laura D. Hughes¹², Xianding Deng⁴, Candace Wang⁴, Venice Servellita⁴, Holly Valentine⁵, Peter De Hoff⁵, Phoebe Seaver⁵, Shashank Sathe⁵, Kimberly Gietzen⁶, Brad Sickler⁶, Jay Antico⁶, Kelly Hoon⁶, Jingtao Liu⁶, Aaron Harding⁷, Omid Bakhtar⁷, Tracy Basler⁸, Brett Austin⁸, Magnus Isaksson¹, Phillip G. Febbo⁶, David Becker¹, Marc Laurent¹, Eric McDonald⁸, Gene W. Yeo⁵, Rob Knight⁵, Louise C. Laurent⁵, Eileen de Feo⁶, Michael Worobey³, Charles Chiu^{4,9}, Marc A. Suchard¹⁰, James T. Lu¹, William Lee^{1,#}, Kristian G. Andersen^{2,11,#}@

LINK:

<https://www.medrxiv.org/content/10.1101/2021.02.06.21251159v1>

- ~35-45% more transmissible
- Doubling frequency ~1.5 weeks
- Potential dominant strain by March 2021
- If correct, anticipate increased surge in cases



PRELIMINARY – NOT PEER REVIEWED

Increased hazard of death in community-tested cases of
SARS-CoV-2 Variant of Concern 202012/01

Nicholas G. Davies^{1†}, Christopher I. Jarvis¹, CMMID COVID-19 Working Group, W. John Edmonds¹, Nicholas P. Jewell^{2,3}, Karla Diaz-Ordaz^{2,3*}, Ruth H. Keogh^{2,3*}

1. Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.

2. Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.

3. Centre for Statistical Methodology, London School of Hygiene and Tropical Medicine, London, UK.

LINK:

<https://www.medrxiv.org/content/10.1>

101/2021.02.01.21250959v1




Fig. S2. Kaplan Meier plots of survival within 60 days of positive test for SGTF versus all other positive SARS-CoV-2 tests by age group. Note that the Y axis differs for each panel.

What is important about the COVID-19 variants?

- Pandemic trajectory
- Double masks
- Monoclonal antibodies
- Vaccinations
- Mandates/restrictions/link to healthcare system impact and activity